Recon: Eli Lilly’s obesity pill assisted in weight loss maintenance after injection switch; Takeda’s AI-generated psoriasis therapy sees Phase 3 success
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Amid talk of a brain drain, some scientists leave U.S. behind (STAT)
- We crunched the numbers on drug discovery in the U.S. vs. China. The results were alarming (STAT)
- Eli Lilly’s obesity pill helped patients maintain weight loss after switch from injections (STAT)
In Focus: International
- Moderna lands CEPI as new backer for its pandemic flu program (Endpoints)
- UK Grapples With Disruption in Supplies of Epidural Infusions (Bloomberg)
- MHRA And HSA Lay UK-Singapore Path To Closer Medtech Harmonization – ‘But SMEs Take Heed’ (MedTech Insight)
- Fragmented Governance Must Be Tackled As Part Of EU Medtech Revision (MedTech Insight)
- Novo files marketing application for next-gen weight-loss drug (Reuters)
- Biotech, growing up, is turning profitable (STAT)
- Takeda's $4B immunology drug achieves first Phase 3 successes (Endpoints)
- After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset (Endpoints)
- Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappoints (Endpoints)
- Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A (Endpoints)
- Atavistik raises $120M for bleeding disorder, blood cancer drugs (Endpoints)
- Insilico advances Hong Kong IPO, eyes $260M raise with Lilly's support (Endpoints)
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies (Reuters)
- Pharma Makes Billions From Cancer Drugs. Do They Work? (Bloomberg)
- Calming nerves with a hot wearable (Endpoints)
- XCath targets better brain aneurysm outcomes with robotic approach (MedTech Dive)
- Moon Surgical adds 5G and Wi-Fi to Maestro robots for cloud-based AI (MedTech Dive)
- Robot developers make strides in 2025 (MedTech Dive)
- Medtech Outlook 2026: AI Integration Deepens As M&A Fuels Growth (MedTech Insight)
- Taste no longer trumps all: How functional foods are changing the rules on flavor (Food Dive)
- Brashears is back at the USDA's top food safety post (Food Safety News)
Government, Regulatory & Legal
- UnitedHealthcare delays controversial RPM policy change (STAT)
- Hospitals owned by real estate investors more likely to close or go bankrupt (STAT)
- In major effort to end gender-affirming care, Trump administration takes aim at hospitals (STAT)
- What I’ve learned by mapping the impacts of NIH cuts (STAT)
- Medicare enrollees to pay 50% less for some drugs in 2025, report says (Reuters)
- Trump to announce Medicare pilot program to pay for CBD treatments, report says (Reuters)
- Consultant: Medicare Payment Changes May Expand Home Cardiac Monitoring and Reshape RPM Market (MedTech Insight)
- New York Giants team doctor: Clinics offering ‘miracle injections,’ ‘next generation cell therapies’ are selling false hope (STAT)
- Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow (STAT)
- Americans facing soaring health insurance costs may get a lifeline in 2026, experts say (Reuters)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
